Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTx-265 in acute ischemic stroke
NCT00938314Phase 2Terminated
- Sponsor
- Stem Cell Therapeutics Corp.
- Start
- Aug 2009
- Primary completion
- Apr 2010
- Modality
- rProtein (Recombinant Protein), Biologic, Combination therapy
- Countries
- 3
01
Overview
A Phase 2 trial of NTx-265 in ischemic stroke, sponsored by Stem Cell Therapeutics Corp.. Started Aug 2009; status: terminated.
02
Drugs
NTx-265
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT00938314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00938314.